New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday 20 November 2026
Export PCSA’s income statement to Excel — free account
Heatwurx Inc.
PCSA- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
1.67
0.03
−1.76%
Follow PCSA
Alert me
Heatwurx Inc. (PCSA) P/E ratio
Heatwurx Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,068× (July 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2016 | 0.0× | — |
| Dec 2015 | 0.0× | — |
| Sep 2015 | 0.0× | — |
| Mar 2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 1,068×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SKYE Skye Bioscience, Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| CANF Can-Fite Biopharma Ltd compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| PCSA Heatwurx Inc. | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | n/m |
| JAGX Jaguar Animal Health, Inc. compare | 0.0× |
| Biotechnology industry median | 8.3× |
| Healthcare sector median | 22.4× |
| Market median | 16.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)